Skip over navigation
Directory
Directory Search
Jobs
Job Search
Post a Job
Patient
Patient Resources
Drug Development
History
Genealogy
Toons & Teasers
About
Advertising
Home
Quick Links
Directory
Job Search
Toons & Teasers
Advertising
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Industry News
Search Articles:
Novartis SEG101 (crizanlizumab) significantly reduces frequency of sickle cell pain crises
Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab), an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises by 45.3% compared to placebo in patients with or without hydroxyurea therapy.
December 03, 2016
More...
Email This Page
to a Friend
Print This
Page